Loading…
Part of AstraZeneca
The rare disease arm of a global biopharmaceutical company, working on complement biology, genomic medicine, and treatments for rare conditions.
Alexion, AstraZeneca Rare Disease / AstraZeneca / Northeastern University / Santa Fe Institute
Released December 15, 2024
Disease embeddings learned from human genetic evidence and phenotype ontologies, placing rare and common conditions in one mechanistic vector space.